A new test developed by researchers from The University of Manchester could revolutionise the discovery of new prescription drugs.
The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available. The findings are published online in the journal Metabolomics.
The pharmaceuticals industry is worth billions of pounds a year. The main source of prescription medicines comes from what are known as 'small molecule' drugs, such as statins and antibiotics.
The main problem for those who would benefit from new medicines, and for the industry, is that most new small molecule drugs never make it out of the door of the drug companies, because – despite early promise – they either do not work or because they show toxicity. Known as 'attrition', this is bad for patients and extremely costly for the pharmaceutical industry and it would help a lot if we could find a rule that most drugs obeyed.
A famous test, colloquially called the 'rule of 5', was developed by Chris Lipinski and colleagues from Pfizer in 1997. The rule sets down four properties that a synthetic i.e. man-made molecule should obey if it is to have a chance of becoming a successful drug.
However, the rule doesn't normally work for naturally-occurring products, that is, drugs with active ingredients that come from nature (penicillin, for example, which is produced by Penicillium fungi). Nearly half of new drugs are based on naturally-occurring substances.
In 2013, researchers at The University of Manchester helped create a ground-breaking computer model that replicates how the human metabolic network works. A kind of 'instruction manual' for how our metabolism interacts with human diseases, this model means scientists now know most of the small molecules that are used by our bodies as part of our normal biochemistry.
Armed with this knowledge, the University's research team, led by Professor Douglas Kell of its School of Chemistry and the Manchester Institute of Biotechnology, compared the structures of all these molecules, known as metabolites, with all marketed drugs (including natural products). They also compared drugs and metabolites with synthetic chemicals from a commercial Maybridge chemical library.
Professor Kell says, ''We immediately saw a very strong correlation. More than 90 per cent of marketed drugs - and we tested over 1300 of the FDA's (Food and Drug Administration) approved drugs - bear a structural similarity of at least 0.5 to at least one metabolite. In other words, they look very like them. This new 'rule of 0.5' does not mean that a molecule obeying it will necessarily become a successful drug, but what it does mean is that we can now say that a molecule that does not obey it, is very unlikely to succeed.''
This new finding should be of considerable value in avoiding the costly problems of attrition, freeing up more resources for developing effective medicines and making them available more quickly for those who need them.